SOURCES SOUGHT
A -- Research and Development Sources Sought
- Notice Date
- 5/27/2009
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- PR68171
- Archive Date
- 6/18/2009
- Point of Contact
- Angelina H. Waring,
- E-Mail Address
-
fwv2@cdc.gov
(fwv2@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- This is not a solicitation and does not guarantee that the Government will proceed with a solicitation or award of a contract in the future. This notice is only for market research purposes. This is a sources sought notice to determine the availability of potential business that can provide the services below. The U.S. Public Health Service recommends that women of childbearing age consume 0.4 mg/day of folic acid to prevent neural tube defects. Folate is a water-soluble essential nutrient that is required for DNA methylation, a critical mechanism of maintaining appropriate gene expression and chromosomal integrity. In controlled metabolic studies, global DNA methylation has been shown to be responsive to changes in folic acid intake, however no study has evaluated dose-dependent methylation changes associated with long term folic acid supplementation. Previous studies indicate that DNA methylation may be negatively affected by a genetic polymorphism (677C→T) which reduces the activity of a key folate enzyme, methylenetetrahydrofolate reductase (MTHFR). Our initial studies have found there are age, dose and genotype dependent changes in global DNA methylation levels in response to folic acid supplementation and withdrawal among certain dosage of folic acid. This first of its kind population based study has generated a number of new hypotheses and requires timely follow-up to begin to elucidate the implications of these findings. We plan to test additional DNA samples (additional dosages and the B12 deficient cohort) for global and site specific changes to determine if there are additional changes in the DNA (uracil) and gene-gene interactions. The purpose of this project is to determine the normal patterns of DNA methylation and levels of uracil mis-incorporation and how these patterns change in response to folic acid supplementation and individual genotypes. The requirement is to utilize global methylation assay - liquid chromatography tandem mass spectrometry to determine the ratio of methylcytosine to cytosine. This effort requires the Contractor to have the capability to perform this technique to yield sensitive and reproducible results with inter and intra assay variation less than 5%. The vendor shall perform the following tasks: DNA extraction Handling, aliquoting, record keeping and storage of samples Genotyping DNA Develop assay to do LC/MS/MS assay global methylation analysis on limited samples on ~10ng of DNA using bisulfite treatment and WGA Global methylation assay- liquid chromatography tandem mass spectrometry will be used to determine the ratio of methylcytosine to cytosine with the samples Uracil misincorporation Reporting of results to Project Officer Interested businesses that believe they possess the capabilities necessary to successfully perform this requirement should submit a hardcopy and an electronic copy of their capability statement, addressing their capability to perform the tasks identified above. Companies must demonstrate their ability and experience in providing these services within the last 36 months. Please limit responses to 5 pages or less. Any proprietary information should be specifically identified as such. References shall include company name, point of contact, telephone number, fax number, and email address. Capability statements shall identify the business status (e.g. large business, small business, 8(a), veteran-owned small business, service-disabled veteran owned small business, HUBZone small business, small disadvantage business, and women owned small business) of the organization. Responses, both electronic and hardcopy, must be received by June 3, 2009 2pm EST. Capability statements will not be accepted after the due date/time. Respondents shall submit their email and hardcopy capability statement to: Electronic: Angelina H. Waring at fwv2@cdc.gov. SUBJECT: PR68171 Capability Statement Hardcopy: Centers for Disease Control and Prevention ATTN: Angelina H. Waring 2920 Brandywine Road, Rm. 3000, M/S E-09 Atlanta, GA. 30341-5539
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/PR68171/listing.html)
- Record
- SN01828529-W 20090529/090527235749-000fb417388cd16d7527eb36e70e86b6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |